Non-profit · founded 2002

Infectious Diseases Institute

Kampala, Uganda · idi.mak.ac.ug

Manage this page

Citations, last 5 years: 9 482
Works, last 5 years: 1 280
h-index: 137
Scientists listed: 0
Grants since 2016: 75

Grants received

2025–2028 · grant · G11

High-Performance Computing for HIV Research Excellence (HPC4HIV)

Daudi Jjingo · Infectious Diseases Institute · funded by National Institutes of Health

$100.7k

2024–2029 · career development · K43

Integrating tuberculosis treatment into community pharmacies to improve TB/HIV outcomes in Uganda.

Jonathan Izudi · Infectious Diseases Institute · funded by National Institutes of Health

$109.7k

2024–2026 · research · R21

Late Neurological Sequelae after Cryptococcal Meningitis

Laura Joan Nsangi · Infectious Diseases Institute · funded by National Institutes of Health

$174.7kFungal Infections and Studies

2024–2029 · career development · K43

Integrating tuberculosis treatment into community pharmacies to improve TB/HIV outcomes in Uganda.

Jonathan Izudi · Infectious Diseases Institute · funded by National Institutes of Health

$109.9k

2024–2026 · research · R21

Late Neurological Sequelae after Cryptococcal Meningitis

Laura Joan Nsangi · Infectious Diseases Institute · funded by National Institutes of Health

$172.7k

2023–2028 · career development · K43

Peer delivered HIV/syphilis self-testing with assisted partner notification services for men who have sex with men (MSM) in Uganda

Stephen Okoboi · Infectious Diseases Institute · funded by National Institutes of Health

$109.9kHIV/AIDS Research and Interventions

2023–2025 · grant · D43

HIV CO-INFECTIONS IN UGANDAAdministrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional)

Barbara Castelnuovo · Infectious Diseases Institute · funded by National Institutes of Health

$131.9k

2023–2026 · research · R01

Ssimusango: Multi-level intervention for intersectional stigma reduction to improve HIV outcomes for transgender women

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$186.2kLGBTQ Health, Identity, and Policy

2023–2026 · research · R01

Ssimusango: Multi-level intervention for intersectional stigma reduction to improve HIV outcomes for transgender women

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$178.1kLGBTQ Health, Identity, and Policy

2023–2028 · career development · K43

Peer delivered HIV/syphilis self-testing with assisted partner notification services for men who have sex with men (MSM) in Uganda

Stephen Okoboi · Infectious Diseases Institute · funded by National Institutes of Health

$109.9kHIV/AIDS Research and Interventions

2023–2027 · research · R01

Ssimusango: A Multi-level intervention to reduce stigma to improve HIV prevention and treatment outcomes for people struggling to access and remain in care

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$172.8k

2023–2028 · career development · K43

Peer delivered HIV/syphilis self-testing with assisted partner notification services for men who have sex with men (MSM) in Uganda

Stephen Okoboi · Infectious Diseases Institute · funded by National Institutes of Health

$109.9k

2022–2025 · research · R01

Choice-Based PrEP Delivery for Transgender People in Uganda

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$478.5kHIV/AIDS Research and Interventions

2022–2027 · research · R01

Choice-Based PrEP Delivery for Transgender People in Uganda

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$519.8kHIV/AIDS Research and Interventions

2021–2026 · research · R01

Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy

Christine Sekaggya-Wiltshire · Infectious Diseases Institute · funded by National Institutes of Health

$138.4k

2021–2026 · career development · K43

Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa

Helen Byakwaga · Infectious Diseases Institute · funded by National Institutes of Health

$101.7kViral-associated cancers and disorders

2021–2026 · career development · K43

Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa

Helen Byakwaga · Infectious Diseases Institute · funded by National Institutes of Health

$101.3kViral-associated cancers and disorders

2021–2026 · research · R01

Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy

Christine Sekaggya-Wiltshire · Infectious Diseases Institute · funded by National Institutes of Health

$140.7k

2021–2022 · grant · D43

HIV CO-INFECTIONS IN UGANDA

Barbara Castelnuovo · Infectious Diseases Institute · funded by National Institutes of Health

$87.9kHIV-related health complications and treatments

2021–2026 · career development · K43

Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa

Helen Byakwaga · Infectious Diseases Institute · funded by National Institutes of Health

$102.9kViral-associated cancers and disorders

2021–2026 · research · R01

Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy

Christine Sekaggya-Wiltshire · Infectious Diseases Institute · funded by National Institutes of Health

$137.7k

2021–2026 · career development · K43

Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa

Helen Byakwaga · Infectious Diseases Institute · funded by National Institutes of Health

$91.6kViral-associated cancers and disorders

2021–2026 · research · R01

Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy

Christine Sekaggya-Wiltshire · Infectious Diseases Institute · funded by National Institutes of Health

$136k

2021–2027 · career development · K43

Quantifying, Explaining and Predicting Survival After Diagnosis of HIV-related Kaposi Sarcoma in East Africa

Helen Byakwaga · Infectious Diseases Institute · funded by National Institutes of Health

$91.2k

2021–2027 · research · R01

Clinical Predictors of weekly Rifapentine/isoniazid related adverse drug reactions during national roll-out of tuberculosis preventive therapy

Christine Sekaggya-Wiltshire · Infectious Diseases Institute · funded by National Institutes of Health

$143.5k

2020–2025 · research · R01

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Ponsiano Ocama · Infectious Diseases Institute · funded by National Institutes of Health

$132.3kParasites and Host Interactions

2020–2025 · research · R01

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Ponsiano Ocama · Infectious Diseases Institute · funded by National Institutes of Health

$135kParasites and Host Interactions

2020–2025 · research · R01

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Ponsiano Ocama · Infectious Diseases Institute · funded by National Institutes of Health

$134.9kParasites and Host Interactions

2020–2025 · research · R01

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Ponsiano Ocama · Infectious Diseases Institute · funded by National Institutes of Health

$130.9kParasites and Host Interactions

2020–2025 · research · R01

Clinical and immunological impact of Schistosoma mansoni infection and treatment on the course of chronic hepatitis B virus (HBV) infection in Uganda

Ponsiano Ocama · Infectious Diseases Institute · funded by National Institutes of Health

$131kParasites and Host Interactions

2019–2022 · research · R34

Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$100kLGBTQ Health, Identity, and Policy

2019–2024 · cooperative agreement · U01

ACUTE FEBRILE ILLNESS IN UGANDA

Andrew Ddungu Kambugu · Infectious Diseases Institute · funded by Centers for Disease Control and Prevention

2019–2024 · cooperative agreement · U01

ACUTE FEBRILE ILLNESS IN UGANDA

Andrew Ddungu Kambugu · Infectious Diseases Institute · funded by Centers for Disease Control and Prevention

2019–2022 · grant · G11

Towards eliminating HIV in Uganda by 2030; Preparing Ethical Review Committees to support this agenda

Pauline Byakika-Kibwika · Infectious Diseases Institute · funded by National Institutes of Health

$99.2kEthics in Clinical Research

2019–2024 · cooperative agreement · U01

ACUTE FEBRILE ILLNESS IN UGANDA

Andrew Ddungu Kambugu · Infectious Diseases Institute · funded by Centers for Disease Control and Prevention

$500k

2019–2022 · research · R34

Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP for Transgender Women in Uganda

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$172.7k

2019–2024 · cooperative agreement · U01

ACUTE FEBRILE ILLNESS IN UGANDA

Andrew Ddungu Kambugu · Infectious Diseases Institute · funded by Centers for Disease Control and Prevention

$273.7k

2019–2024 · cooperative agreement · U01

ACUTE FEBRILE ILLNESS IN UGANDA

Andrew Ddungu Kambugu · Infectious Diseases Institute · funded by Centers for Disease Control and Prevention

2019–2023 · research · R34

Peer-Delivered HIV Self-Testing, STI Self-Sampling and PrEP for Transgender Women in Uganda

Andrew Mujugira · Infectious Diseases Institute · funded by National Institutes of Health

$159k

2019–2022 · grant · G11

Towards eliminating HIV in Uganda by 2030; Preparing Ethical Review Committees to support this agenda

Pauline Byakika-Kibwika · Infectious Diseases Institute · funded by National Institutes of Health

$99.3kEthics in Clinical Research